Scope
NICE guideline NG185 on acute coronary syndromes covers early management of STEMI and of NSTEMI and unstable angina. It also covers hyperglycaemia during and after an acute coronary syndrome, drug therapy for secondary prevention after myocardial infarction, and cardiac rehabilitation and lifestyle change. Individual recommendations are dated from 2007 to 2020, and several defer to NICE technology appraisals or other NICE guidelines.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
STEMI: assessment and reperfusion
- In acute STEMI, assess eligibility for reperfusion (primary PCI or fibrinolysis) immediately, regardless of age, ethnicity or sex. Deliver reperfusion as quickly as possible to eligible patients. After cardiac arrest from suspected STEMI, level of consciousness should not decide eligibility for angiography. [1]
- Give a single 300 mg aspirin loading dose as soon as possible unless allergy is clearly evident. When primary PCI is planned, avoid routine glycoprotein IIb/IIIa inhibitors or fibrinolytics before arrival in the catheter laboratory. [1]
- Angiography with follow-on primary PCI if indicated is the preferred strategy when two conditions are met: presentation is within 12 hours of symptom onset, and PCI can be delivered within 120 minutes of when fibrinolysis could have been given. Angiography with follow-on primary PCI if indicated is also offered in cardiogenic shock presenting within 12 hours of symptom onset. [1]
- For presentation more than 12 hours after symptom onset, consider angiography with follow-on primary PCI if ischaemia is continuing. If cardiogenic shock is present or develops, consider angiography with a view to revascularisation. [1]
- Offer fibrinolysis within 12 hours of onset if primary PCI cannot be delivered within 120 minutes of when fibrinolysis could have been given, with an antithrombin given at the same time. Consider same-admission angiography for patients who are clinically stable after successful fibrinolysis. [1]
- Offer an ECG 60 to 90 minutes after fibrinolysis. Residual ST-segment elevation suggesting failed reperfusion calls for immediate angiography, with PCI if indicated, rather than repeat fibrinolysis. [1]
Primary PCI: adjunctive therapy and revascularisation
- For primary PCI, offer prasugrel with aspirin unless the patient already takes an oral anticoagulant; in that case, offer clopidogrel with aspirin. In people aged 75 and over, if prasugrel's bleeding risk outweighs its effectiveness, offer ticagrelor or clopidogrel. [1]
- With radial access, offer unfractionated heparin plus a bailout glycoprotein IIb/IIIa inhibitor alongside dual antiplatelet therapy. When femoral access is needed, consider bivalirudin with a bailout inhibitor; this use with prasugrel and aspirin was off label in November 2020. [1]
- In multivessel disease without cardiogenic shock, offer complete PCI revascularisation and consider doing it during the index admission. With cardiogenic shock, consider culprit-vessel-only PCI rather than complete revascularisation at the index procedure. When stenting is indicated, offer a drug-eluting stent for PCI in STEMI, unstable angina or NSTEMI. [1]
NSTEMI and unstable angina: early management
- Offer aspirin as soon as possible, with a single 300 mg loading dose unless allergy is clearly evident. Continue it indefinitely unless bleeding risk or hypersensitivity contraindicates it. Do not give dual antiplatelet therapy for chest pain before the diagnosis is made. [1]
- Offer fondaparinux when bleeding risk is not high, unless immediate angiography is planned. Give systemic unfractionated heparin in the catheter laboratory during PCI whether or not fondaparinux was received; this was off label in November 2020. If creatinine is above 265 micromoles per litre, consider monitored, dose-adjusted unfractionated heparin instead of fondaparinux. [1]
- Once the diagnosis is made and aspirin and antithrombin have been offered, formally assess risk with a score predicting 6-month mortality, such as GRACE. Include a resting 12-lead ECG and blood tests such as troponin, creatinine, glucose and haemoglobin in this assessment. Use the result to guide management, balancing benefit against harm. [1]
- Offer immediate angiography if the patient is clinically unstable. Consider angiography, with PCI if indicated, within 72 hours of admission when predicted 6-month mortality exceeds 3.0% and there is no contraindication such as active bleeding or comorbidity. If initial risk is low (3.0% or less), consider angiography when ischaemia occurs or is demonstrated. Some younger low-score patients may still be at high risk. [1]
- For low-risk patients (predicted 6-month mortality 3.0% or less), consider conservative management without early angiography. If managed conservatively without angiography, consider pre-discharge ischaemia testing. [1]
- For angiography, offer prasugrel or ticagrelor with aspirin if there is no separate indication for ongoing oral anticoagulation; otherwise offer clopidogrel with aspirin. Give prasugrel only once anatomy is defined and PCI is intended, and weigh its bleeding risk in people aged 75 and over. [1]
- For STEMI not treated with PCI, and for unstable angina or NSTEMI when PCI is not indicated, offer ticagrelor with aspirin unless bleeding risk is high. If bleeding risk is high, consider clopidogrel with aspirin, or aspirin alone. Offer medical management to STEMI patients ineligible for any reperfusion. [1]
Hyperglycaemia in acute coronary syndromes
- For inpatients, keep blood glucose below 11.0 mmol/litre while avoiding hypoglycaemia. Consider a dose-adjusted insulin infusion with regular monitoring first. Do not routinely use intensive insulin–glucose infusion unless clinically indicated. [1]
- In hyperglycaemia without known diabetes, test HbA1c before discharge and fasting glucose no earlier than 4 days after onset, without delaying discharge. Avoid routine oral glucose tolerance tests if both are normal. Advise patients of their increased type 2 diabetes risk, and ask GPs to monitor at least annually. [1]
Secondary prevention and cardiac rehabilitation after MI
- Start an ACE inhibitor once haemodynamically stable and continue it indefinitely. Titrate at short intervals, for example every 12 to 24 hours, toward the maximum tolerated or target dose before discharge, or complete titration within 4 to 6 weeks after discharge. Use an ARB if the patient is intolerant. Avoid combining an ACE inhibitor with an ARB without other reasons. [1]
- Continue dual antiplatelet therapy for up to 12 months after MI unless contraindicated. Continue aspirin indefinitely unless the patient is intolerant or anticoagulation is indicated. Consider clopidogrel monotherapy for aspirin hypersensitivity. [1]
- After PCI in patients already anticoagulated, continue the anticoagulant with clopidogrel for up to 12 months. With a new anticoagulation indication after PCI, offer clopidogrel in place of prasugrel or ticagrelor for up to 12 months plus a licensed oral anticoagulant. Avoid routinely combining prasugrel or ticagrelor with an anticoagulant needed for an ongoing separate indication. [1]
- For people with an anticoagulation indication who have not had PCI (medical management or CABG), continue anticoagulation and, unless bleeding risk is high, consider continuing aspirin, or clopidogrel if aspirin is contraindicated, for up to 12 months. For people with a separate indication for anticoagulation, be aware that the optimal duration of aspirin has not been established and that long-term triple therapy with aspirin, clopidogrel and an oral anticoagulant significantly increases bleeding risk. [1]
- Offer a beta-blocker as soon as possible once haemodynamically stable. Without reduced ejection fraction, consider continuing it for 12 months, then discuss the benefits and risks of stopping or continuing. With reduced ejection fraction, continue it indefinitely. [1]
- Advise and offer cardiac rehabilitation with an exercise component to everyone, regardless of age. Begin before discharge, with a first session within 10 days of discharge. After uncomplicated recovery, sexual activity can usually resume after about 4 weeks. [1]
Limitations and use
- Covers the clinical recommendations chapter only; research recommendations and committee rationale or impact discussion are not summarised as guidance.
- Visual summaries and algorithms referenced by NICE are not reproduced.
- Several recommendations defer to NICE technology appraisals (for example, prasugrel, ticagrelor, rivaroxaban, glycoprotein IIb/IIIa inhibitors, thrombolytics, semaglutide) or to other NICE guidelines (chronic heart failure, lipid modification, hypertension, dyspepsia, tobacco, obesity), whose details are not included.
- Recommendations carry individual dates from 2007 to 2020; some reflect licensing status as of November 2020, including off-label uses.
- Not every recommendation is summarised, including calcium channel blockers, nicorandil, aldosterone antagonists, device therapy, detailed rehabilitation delivery, dietary and lifestyle advice, and communication of discharge information.
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- Acute coronary syndromes
Guideline recommendation text consulted
Publication details
- Issuing organisation
- NICE
- First published
- 18 November 2020
- Resource type
- Clinical guideline · House clinical summary
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.